Form 8-K - Current report:
SEC Accession No. 0001437749-24-037373
Filing Date
2024-12-12
Accepted
2024-12-12 16:36:50
Documents
16
Period of Report
2024-12-10
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20241205_8k.htm   iXBRL 8-K 59596
2 EXHIBIT 3.1 ex_754381.htm EX-3.1 10561
7 ex31.jpg GRAPHIC 107195
  Complete submission text file 0001437749-24-037373.txt   375350

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvph-20241210.xsd EX-101.SCH 3914
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20241210_def.xml EX-101.DEF 13857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20241210_lab.xml EX-101.LAB 18275
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20241210_pre.xml EX-101.PRE 13889
18 EXTRACTED XBRL INSTANCE DOCUMENT rvph20241205_8k_htm.xml XML 4983
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 241545390
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)